PAREXEL INTRODUCES NEW MEDICAL AND SCIENTIFIC OFFERING
BOSTON, MA, May 15, 2001 — Perceptive Informatics, Inc. (Perceptive), a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), and Spotfire, Inc. today announced that they have formed a strategic alliance designed to speed the drug development process. Perceptive will integrate Spotfire DecisionSite into its web-based portal products and distribute the combined offering with a goal toward improving the speed and accuracy of decision-making throughout the stages of drug development. Spotfire DecisionSite has been incorporated into Perceptive’s web solutions that provide on-line, real-time access to clinical trial data. This integrated offering may enable users to perform interactive visualization and information analysis to uncover key trends in bio/pharmaceutical research faster.
“Perceptive Informatics is pleased to be able to offer Spotfire DecisionSite to clinical development organizations. We believe that combining the data access provided by our portal products with the analytical power of Spotfire DecisionSite can improve a client’s ability to monitor clinical trial findings and rapidly identify and respond to emerging trends,” said Mark A. Goldberg, M.D., President of Perceptive Informatics, Inc. “As a Vertical Service Provider (VSP) to the Bio/Pharmaceutical industries, we offer information technology tools designed to reduce the time, cost and risk associated with clinical development and launch programs. Our depth of expertise in clinical development enables us to successfully deploy innovative platform technologies to the clinical development arena.”
“Perceptive’s record in applying technology for the enhancement of clinical development will further the deployment of Spotfire DecisionSite in this segment,” said Joseph F. Donahue, Spotfire Vice President, Worldwide Life Sciences Market. “Our information interaction capabilities are well-suited to this data-intensive process, and together we believe we can add real value to the clinical development process.”
Perceptive Informatics, Inc. develops and offers a portfolio of sophisticated and innovative technology-based products and services that facilitate clinical drug development and are designed to decrease time to peak sales. The technology portfolio includes web-based portal solutions, Interactive Voice Response Systems (IVRS), electronic data capture, and electronic diary solutions. Perceptive also offers advanced medical diagnostics services to assess rapidly and objectively the safety and efficacy of new drugs, biologics, and medical devices in clinical trials. The Company is headquartered near Boston, MA with approximately 150 employees in offices located throughout North America and Europe. Perceptive Informatics is a subsidiary of PAREXEL International Corporation, one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries.
Spotfire, Inc. is a leading provider of eAnalytic applications and services that put the power of decision-making at the center of its customers’ businesses. Spotfire's solutions enable organizations around the world to improve the efficiency, the speed and the accuracy of their decision-making processes by advancing both individual and networked analysis. More than 350 customers and over 16,000 subscribers use Spotfire products worldwide. The company maintains U.S. headquarters in Somerville, Mass. and European headquarters in Göteborg, Sweden. Additional information can be found at http://www.spotfire.com.
Spotfire is a registered trademark and DecisionSite is a trademark of Spotfire, Inc. All other names or marks may be registered trademarks or trademarks of their respective owners and are hereby acknowledged.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. PAREXEL's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; PAREXEL's dependence on certain industries and clients; PAREXEL's ability to manage growth and its ability to attract and retain employees; PAREXEL's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of PAREXEL's Form 10-Q for the period ended December 31, 2000 as filed with the Securities and Exchange Commission.